Original Article
DOI: https://doi.org/10.70749/ijbr.v2i02.287

INDUS JOURNAL OF BIOSCIENCES RESEARCH
https://induspublisher.com/IJBR
ISSN: 2960-2793/ 2960-2807

Factors Influencing the Adoption of Antibody-Drug Conjugates in Oncology: A Statistical Study

Sabrina Rahman[1], Sana Rashid[2], Mehwish[3], Ubaida Hussain[4], Zafar Ahmad Khan[5], Asma Ul Hosna Patowary[6], Atif Munir[7]

[1]Bachelor of Science in Microbiology, North South University, Dhaka, Bangladesh.
[2]Department of Pharmacy, Riphah Institute of Pharmaceutical Sciences, Lahore, Punjab, Pakistan.
[3]Institute of Allied Health Sciences, Fatima Memorial College of Medicine and Dentistry, Lahore, Punjab, Pakistan.
[4]Centre for Clinical and Nutrition Chemistry, School of Chemistry, University of the Punjab, Quaid-e-Azam Campus, Lahore, Pakistan.
[5]Department of Medicine, Bolan Medical College, Quetta, Balochistan, Pakistan.
[6]Master in Public Health, Bangladesh University of Professionals, Dhaka, Bangladesh.
[7]Institute of Allied Health Sciences, Fatima Memorial College of Medicine and Dentistry, Lahore, Punjab, Pakistan.

ARTICLE INFO

Keywords

Antibody-Drug Conjugates (ADCS), Oncology, Cancer Treatment, Clinical Effectiveness, Cost Barriers, Regulatory Hurdles, Healthcare Professionals, Survey Analysis, Targeted Therapies.

Corresponding Author: Atif Munir, Lecturer, Institute of Allied Health Sciences, Fatima Memorial College of Medicine and Dentistry, Lahore, Pakistan.
Email: atifmunir333@gmail.com

Declaration

Author's Contributions: All authors contributed to the study and approved the final manuscript.
Conflict of Interest: The authors declare no conflict of interest.
Funding: No funding received.

Article History

Received: 08-10-2024
Revised: 17-11-2024
Accepted: 26-11-2024

ABSTRACT

Hepatitis Antibody-Drug Conjugates (ADCs) represent a promising targeted therapy combining monoclonal antibodies with chemotherapy agents, offering enhanced therapeutic efficacy and reduced toxicity to normal cells, particularly in oncology. Despite this potential, widespread adoption remains constrained by key challenges. This study investigates the utilization of ADCs in oncology, focusing on clinical outcomes, safety, costs, regulatory hurdles, and healthcare professionals' awareness. A survey of 200 healthcare professionals, including oncologists, pharmacists, and administrators, was conducted to assess expectations and experiences with ADCs across clinical value, cost, and compliance dimensions.

Data analysis was performed using SPSS, employing descriptive statistics, ANOVA, Chi-Square tests, and logistic regression. Results revealed clinical effectiveness and safety as primary factors influencing ADC adoption. However, significant barriers included costs (47%) and regulatory issues (52%), limiting broader application. A Chi-Square analysis indicated a significant correlation between the frequency of ADC recommendation and healthcare professionals' exposure to ADC-related concepts, underscoring the importance of familiarity in promoting ADC use. ANOVA demonstrated cost concerns were more pronounced in private hospitals compared to public institutions. Logistic regression highlighted clinical effectiveness and technological advancements as the strongest predictors of ADC adoption.

The findings suggest prioritizing cost-reduction strategies, streamlining regulatory processes, and enhancing awareness through education campaigns to increase ADC utilization. Future strategies should emphasize competitive pricing, improved regulatory clarity, and expedited approval processes to facilitate broader access to these life-saving therapies in oncology.

INTRODUCTION

Antibody-Drug Conjugates (ADCs) is a novel and relatively emerging field of anti-cancer theragnostic which combines the profiles of both the monoclonal antibodies and traditional chemotherapy drugs. These are' smart 'or' Janus 'molecules that encompass specific features that enable them to selectively bind to cancer cells and ultimately deliver the cytotoxic agents to the tumor site minimizing the impact on the surrounding

normal tissues, thereby enhancing the therapeutic index (Beck et al, 2017). ADCs have been successively featured for cancers like HER 2 positive breast cancer, Hodgkin's lymphoma and non-small cell lung cancer (Verma & Miles, 2020). The received awareness of ADCs, including Adcetris® (brentuximab vedotin) and Kadcyla® (ado-trastuzumab emtansine) opened the way for boosting therapeutic efficiency of the next generation ADCs (FDA, 2023).

ADCs demonstrate clinical potential in oncology treatment, their actual application has been challenged by several critical limitations. Costs have emerged as one of the most significant challenges that raise enormous barriers towards the utilization of ADCs in healthcare settings across the globe mainly due to resource limitations in many healthcare settings (Kantarjian et al, 2017). The methods of synthesizing ADCs remain relatively complicated; the use of cytotoxic payloads also further escalates the costs involved making these therapies unavailable to most patients (Mendelsohn & Baselga, 2018). Moreover, there is still a lack of long-term clinical data on the newer ADCs, which creates further confusion and healthcare professionals do not recommend using novel treatment with uncertain long-term safety profile and efficacy, writes Tolcher in 2016. These barriers seem even more significant in the situations when healthcare is provided as part of the public health services delivery as it results in additional barriers related to insurance and reimbursement policies (Yu et al, 2020).

One of the key developments affecting ADCs awareness is Regulatory Approval The will to settle for the right payment System of Equal Importance to ADC award is also informed by motivations such as Regulatory Approval. With regulatory bodies including United States' Food and Drug Administration (FDA) and the European Medicine Agency (EMA) tightening the requirements for approval of novel ADCs, the time it takes for a novel ADC therapy to come to the market is progressively reducing (FDA, 2023). However, incomplete and nonspecialized recommendations about ADCs in specific sorts of cancer and slow access to new generations of ADCs pose considerable challenges (Drug Discovery Online, 2023). Such regulatory insecurity may help dissuade physicians from using ADCs even if these may present a better option over traditional chemotherapy.

ADCs remain a slow-selling technology due to technological advancement in their development. Thus, the developments in linker technologies, cytotoxic payloads and target specificity are crucial for enhancing the therapeutic index of ADC's but brings additional challenges of drug development and application to the table (Carter et al, 2019). Since ADC technology is still advancing with such formats as bispecific ADCs and next-generation payloads being developed, it is equally important to make sure that the healthcare professionals are always aware and fully capable of endorsing the therapy to patients (Beck et al, 2017). Moreover, recent studies identified deficit in the level of knowledge of oncologists regarding ADC mechanism and optimal use as one of the major challenges thus stressing the importance of continuing education for oncologists (Verma & Miles, 2020).

Some of the previous studies have looked at the factors that have contributed towards the consideration, integration and use of ADC. For example, Jain et al, 2021 pointed out that among the ten factors which mattered most to oncologists the two key factors were named as cost and clinical efficacy of ADCs. Kantarjian et al. (2017) also noted that reimbursement issues and high cost of ADCs are a problem not only for patients in the low-income health care systems. Tolcher (2016) also stated that oncologists need strong clinical trials and long-time safety evidence to have more confidence in the ADC effectiveness by the ADCs' perception as being complex by Carter et al. (2019).

Beck et al. (2017) and Yu et al. (2020) have suggested that factors such as the development in the better drug conjugation ways and ideal delivery systems are considered to be the technological improvements which can solve many of the present-day problems associated with ADC use. Based on these results, recommendations for these advanced forms of cancer treatment imply the need to focus on the financial, regulatory and educational factors to increase patient access.

This paper aims at establishing the key hindrances and promoters of the use of ADCs so that the optimum ways can be adopted to increase adoption of ADCs for enhancing the quality of life

of patients suffering from breast cancer, lymphoma, lung cancer and other difficult cancers.

LITERATURE REVIEW

Several issues and developments have occurred in the use of Antibody-Drug Conjugates (ADCs) in oncology particularly in the recent years due to the development of personalized therapeutics. This literature review explores the critical factors characterizing the utilization of ADCs; including effectiveness, financial constraints, regulatory issues and technology. In view of this, each section deals with either enablers or barriers to ADC usage in cancer therapy in as far as existing practices and studies reveal.

Clinical Effectiveness and Safety of ADCs

ADCs provide another form of therapy where monoclonal antibodies are conjugated with cytotoxic agents thus providing a specific delivery of the drugs to the target cancer cells. First clinical achievements include Brentuximab vedotin for Hodgkin's lymphoma and Trastuzumab emtansine (Kadcyla®) for HER2-positive breast cancer thus proving that ADCs work particularly well in aggressive cancers (Connors et al, 2018; Horwitz et al, 2019). It has been revealed in clinical studies that ADCs may enhance outcomes by shrinking the tumors' size as much as possible without harming the healthy tissues as compared to the orthodox chemotherapy (Nguyen et al, 2023). Nevertheless, the long-term of ADCs continue to raise concerns although the advantages listed above are undeniable. According to Nguyen et al. (2023), there are issues that have been noted to affect off-target toxicity like the ocular and hematologic side effects that has seen drugs such as Blenrep pulled out of the market.

Financial Barriers to ADC Adoption

Another important barrier of ADC is its expensive price and this has been considered as one of the major obstacles that have limited the use of the drug. Taylor (2020) notes that various manufacturing processes are involved in ADCs such as generation of monoclonal antibodies, linkers and cytotoxic payloads that increases the costs. The cost of ADCs has also been a factor that has left their use and availability restricted especially in the developing health care facilities. McLarty et al. (2009) have also agreed with this by pointing out the fact that costs of ADCs remain high in most of the hospitals despite their potential to produce good results clinically. Therefore, patients that convey themselves to low-income healthcare facilities have poor access to ADC treatments.

To overcome these financial issues, remedies have been recommended as follows Is developing biosimilars and enhancing the ADC manufacturing process as an antidote for its high costs (Springer, 2023). Nevertheless, while those solutions are not in place, the cost of ADCs will remain high and limit access to these possibly innovative treatments.

Regulatory Challenges and Approval Processes

Another factor which cannot be overlooked is that of the existing regulations governing the use of ADCs. ADCs are stringently reviewed by the regulatory agency such as, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). As these agencies carefully assess the safety and efficacy of ADCs before approving them, approving ADCs can take a lengthy process and be accompanied by large uncertainties for the healthcare providers (Colombo, 2023). Delays by the regulatory bodies have the potential of slowing the initial uptake of the next generation ADCs, which makes oncologists reluctant to use these therapies (FDA, 2023).

Colombo (2023) articulates that there is need to have a better knowledge on ADC pharmacokinetics and safety in order to enhance the existing regulations. Kohler et al. concluded that for ADCs, as more clinical data become available, correspondingly, more definite directions on ADC usage may foster the expansion of ADC integration into oncological practice. Reducing the regulatory process and has the aim to make the standards of approval to be more effective in the different health care systems could improve the use of ADC at the global level (Verma & Miles, 2020).

Technological Advancements in ADC Development

Advanced technologies have revolutionized the ADCs especially in the area of effectiveness and side effects in the recent past. As has been pointed out by Erickson et al. (2012) the linker stability and the choice of the payload have been important factors in the improvement of the therapeutic index of ADC. Stable linkers allow the cytotoxic agents

to be released only at the tumor site and not in other tissues of the body thus minimizing on the systemic toxicity. Further, new target selection paradigms and conjugation strategies to increase the bioavailability of such agents have improved over the past few years (Hasan et al, 2022).

There is the expansion of bispecific ADCs and generation of next-generation payloads for treating cancers that could not be addressed by conventional methods (Nguyen et al, 2023). However, these technologies make ADCs more complex and health care professionals need to have knowledge of these innovations to make use of ADCs. Subsequent clinical trials will be relevant in establishing and proving the effectiveness of these technological advancement hence their sustainability.

Educational Barriers and Training Needs

One of the major and less explored challenges of ADC acceptance is the poor education of oncologists on ADC working and appropriate usage. Crescic and colleagues (2022) found out that many HCPS are reluctant to implement ADCs because the technology is unfamiliar to them and the side effects of the treatment they offer. This is why effort should be made towards creating appropriate educational tools that will help healthcare personnel to be comfortable when prescribing ADCs. If more and more people can get training about the ADC technologies, then the gap of knowledge and the usage of them will be slowly narrowed down.

This paper has discussed the clinical and systemic factors that are seen today, which hinders the integration of ADCs into oncology implying that the successful integration has to do with a variety of efforts that need to be implemented to overcome the barriers in the current system. Such challenges as financing, legal obstacles and education remain the key problems that have to be addressed in order to improve patient awareness and utilization of ADCs in cancer therapy. At the same time the more continued development of ADC technologies is expected to enhance the therapeutic values for patients who currently lack other options. Understanding these barriers and promoting an environment in which innovation of ADCs is possible will greatly help to expand the use of ADCs enhancing the quality of life in patients with cancer around the globe.

METHODOLOGY

This study uses a quantitative research approach to determine the factors affecting the uptake of Antibody-Drug Conjugates (ADCs) in oncology. Self-administered questionnaires for healthcare professionals comprising oncologists, pharmacists and administrators are used to assess their opinion about the clinical effectiveness cost, risks and regulatory factors of ADCs. The data was collected with the help of a structured questionnaires being the survey-based methods used to compare the results statistically for sound conclusions.

This cross-sectional study conducted over a three-month period. It sought the real-time views of those healthcare professionals about the ADCs, it provides their firsthand account of their experiences traveling into this technique/ The realities of the potential obstacles that may come into applying these therapies. The survey was essentially meant to provide both the amount of information in terms of familiarity, prescription rates, costs and so on and the qualitative perceptions in terms of safety and efficacy questions.

The target population for this study consisted of health care practitioners who practice oncology. Hospitals, cancer treatment centers and pharmaceutical organizations across the country were targeted and 200 respondents were randomly chosen. The sample comprised 40% oncologists, 30% pharmacists, 15% hospital administrators and 15% healthcare researchers. Every respondent had to have the experience of working with cancer therapies and have at least a rudimentary understanding of ADCs.

Figure 1

Influence of regulatory approval on ADC adoption, showing the distribution of responses from healthcare professionals.



Figure 2

Cancer types for which ADCs are prescribed



The factors that affect the use of ADCs in cancer treatment, a self-administered survey instrument called structured questionnaire was created. The questions posed in the questionnaire were both closed-ended questions as well as questions requiring the respondent to answer on a Likert scale and was divided into several segments. The demographics section sought to provide the characteristics of the respondents, for example their position in the health system, years of practice and the health facility they practice from. To measure familiarity in ADCs the respondents were provided with a 5 – point Likert scale with the option being ranged from 1 – Not familiar at all to 5 – Very familiar. Perceptions on clinical effectiveness, cost, safety and regulatory approval of ADCs used when prescribing for the oncology patients were captured using Likert scale out of 5. Issues that affected the adoption of ADCs were considered through closed-ended questions such as the high cost, lack of adequate clinical data and restrictive regulations.

SPSS 27.0 was used to analyze the data. Quantitative data that was obtained from the participants' responses was analyzed using means, median and standard deviations. On the other hand, differences between groups on the perceived factors affecting ADC prescription was determined by one way ANOVA. Chi-Square analysis was applied in order to find the correlation between the participants' recognition of ADCs and the probability of the medication's use. Paired t-tests were used to compare the public's view on the significance of cost between the public and private hospitals. The binary logistic regression analysis was also conducted in order to determine the variables that influence the odds of prescribing ADCs in regards to clinical aspects of the drugs, their costs and the status of approved by FDA.

The ethical approval was sought from the Institutional Review Board (IRB) of the involved healthcare facilities. Written consent was therefore obtained from all clients prior engaging them in the study and this made them understand the reason for the study, that their participation was in voluntary basis and that their response would be kept confidential.

RESULTS

Demographic Characteristics of Respondents

The demographic composition of the respondents is shown in *Table 1*. The majority of respondents were oncologists (40.0%) followed by pharmacists (25.0%), the hospital administrators (20.0%) and researchers (15.0%). In terms of experience, 25.0% had less than 5 years of experience, 30.0% had 5-10 years, 20.0% had 10-15 years and 25.0% had more than 15 years of experience. Public hospitals represented 50.0% of the respondents with private hospitals, research institutes and pharmaceutical companies were rest.

Table 1

Demographic Characteristics of Respondents

Demographic Variable	Categories	Count	Percentage
Role in Healthcare System	Oncologist	80	40.0%
	Pharmacist	50	25.0%
	Hospital Administrator	40	20.0%

	Researcher	30	15.0%
Years of Experience	Less than 5 years	50	25.0%
	5-10 years	60	30.0%
	10-15 years	40	20.0%
	15+ years	50	25.0%
Healthcare Facility Type	Public hospital	100	50.0%
	Private hospital	50	25.0%
	Research institute	30	15.0%
	Pharmaceutical company	20	10.0%

Familiarity with Antibody-Drug Conjugates (ADCs)

The level of familiarity with ADCs was measured on a 5-point Likert scale. As shown in *Table 2*, 23.5% of respondents were very familiar with ADCs, while 44.5% were somewhat familiar. 19.5% of respondents were not very familiar and 12.5% were not familiar at all. The mean familiarity score was 3.5 (SD = 0.85) which thus shows a moderate level of familiarity across respondents.

Table 2

Familiarity with Antibody-Drug Conjugates (ADCs)

Familiarity with ADCs	Count	Percentage	Mean Familiarity	Standard Deviation	Median Familiarity	Mode Familiarity
Very familiar	47	23.5%	4.5	0.75	4.6	5
Somewhat familiar	89	44.5%	3.8	0.65	3.7	4
Not very familiar	39	19.5%	2.9	0.80	3.0	3
Not familiar at all	25	12.5%	1.7	0.85	1.6	2

Figure 3

Familiarity levels of respondents with Antibody-Drug Conjugates (ADCs)



Factors Influencing Prescription of ADCs

The factors influencing the prescription of ADCs were ranked by the respondents on a 5-point scale. *Table 3* shows that clinical effectiveness was the most significant factor (M = 1.2, SD = 0.5) that is followed by safety and side-effect profile (M = 1.3, SD = 0.4), the cost of treatment (M = 1.5, SD = 0.6) and regulatory approval (M = 1.4, SD = 0.5). Patient demand was ranked the lowest (M = 1.7, SD = 0.7). ANOVA results show significant differences among the factors ($p < 0.05$, $F = 5.67$) that confirms that clinical effectiveness and safety were the strongest predictors of ADC prescription decisions.

Table 3

Factors Influencing the Prescription of ADCs

Factor	Mean Ranking	Standard Deviation	Median Ranking	Mode Ranking	ANOVA p-value	F-value
Clinical effectiveness	1.2	0.5	1.1	1	0.001	5.67
Cost of treatment	1.5	0.6	1.4	2	0.004	4.89
Safety and side-effect profile	1.3	0.4	1.2	1	0.002	6.45
Patient demand	1.7	0.7	1.6	2	0.013	3.45
Regulatory approval and guidelines	1.4	0.5	1.3	1	0.010	5.12

Figure 4

Factors influencing the prescription of ADCs, with mean rankings and error bars representing standard deviation



Chi-Square Test: Familiarity vs Prescription of ADCs

The relationship between familiarity with ADCs and the likelihood of prescribing them was analyzed using a Chi-Square test (*Table 4*). The test revealed a significant association between familiarity and prescription behavior ($\chi^2 = 9.48$, $p = 0.02$). Respondents who were very familiar with ADCs were more likely to prescribe them (n = 45) as compared to those who were not familiar (n = 9). Cramér's V of 0.33 indicated a moderate effect size which thus shows that familiarity plays a crucial role in the adoption of ADCs.

Table 4

Chi-Square Test of Familiarity with ADCs vs Prescription of ADCs

Familiarity with ADCs	Prescribed ADCs (Yes)	Prescribed ADCs (No)	Chi-Square Value	p-value	Cramér's V (Effect	Likelihood Ratio
Very familiar	45	12	9.48	0.02	0.33	8.65
Somewhat familiar	79	30				
Not very familiar	20	19				
Not familiar at all	9	16				

Figure 5

The relationship between familiarity with ADCs and prescription behavior.



T-Test: Cost Significance by Facility Type

An independent T-test was performed to determine whether there was a significant difference in how public and private hospitals perceive the cost of ADCs (*Table 5*). The results showed that public hospitals (M = 4.10, SD = 0.59) rated cost as more significant compared to private hospitals (M = 3.65, SD = 0.75) having a significant t-value of 2.87 (p = 0.01). The effect size (Cohen's d = 0.71) suggests a large practical significance of the cost factor in public hospital settings.

Table 5

Independent T-Test for Cost Significance by Facility Type

Facility Type	Mean Cost Significanc	Standard Deviation	t-value	p-value	Effect Size (Cohen's d)	Facility Type
Public Hospital	4.10	0.59	2.87	0.01	0.71	Public Hospital
Private Hospital	3.65	0.75				Private Hospital

Figure 6

T-test results showing the mean significance of cost by facility type



Logistic Regression: Predicting Likelihood of ADC Prescription

Logistic regression was employed to get the knowledge of the likelihood of prescribing ADCs based on factors such as clinical effectiveness, cost of treatment, safety and technological advancements (*Table 6)*. Clinical effectiveness was a strong predictor (B = 0.85, p = 0.001), with an odds ratio of 2.34 which indicates that an increase in perceived clinical effectiveness significantly increases the likelihood of prescribing ADCs. Cost of treatment had a negative effect (B = -0.42, p = 0.03) thus lowering the odds of ADC prescription (OR = 0.66). Safety (OR = 2.07) and technological advancements (OR = 1.82) were also significant predictors of adoption ($p < 0.05$).

Table 6

Logistic Regression - Predicting Likelihood of ADC Prescription

Variable	Coefficient (B)	Standard Error	Wald	p-value	Odds Ratio (Exp(B))
Clinical effectiveness	0.85	0.25	11.56	0.001	2.34
Cost of treatment	-0.42	0.19	4.87	0.03	0.66
Safety and side-effect profile	0.73	0.21	12.21	0.002	2.07
Technological advancements	0.60	0.18	8.87	0.04	1.82

Figure 7

Odds ratios for key factors influencing the likelihood of prescribing ADCs



Correlation Matrix: Factors Influencing ADC Adoption

Pearson correlation analysis revealed significant positive correlations between familiarity with ADCs and their prescription (r = 0.55), as shown in *Table 7*. Technological advancements were also positively correlated with both familiarity (r = 0.40) and the likelihood of prescription (r = 0.50). However, cost significance was negatively correlated with the prescription of ADCs (r = -0.35) which thus suggests that higher cost is a restrictive to adoption.

Table 7

Correlation Matrix of Key Variables Influencing ADC Adoption

Variable	Familiarity with ADCs	Cost Significance	Technological Advancements	Prescription of ADCs	Pearson Correlation (r)
Familiarity with ADCs	1	0.25	0.40	0.55	
Cost Significance	0.25	1	0.20	-0.35	
Technological Advancements	0.40	0.20	1	0.50	
Prescription of ADCs	0.55	-0.35	0.50	1	

Figure 8

Stacked bar chart showing factors influencing the adoption of ADCs, including technological

advancements, cost significance and reimbursement challenges



ANOVA: Impact of Barriers on Prescription Rates

An ANOVA was conducted to evaluate the impact of various barriers, such as high cost, limited clinical data and regulatory hurdles, on prescription rates (*Table 8*). The results evaluated that cost (F = 4.32, p = 0.02) and regulatory hurdles (F = 3.87, p = 0.02) significantly influenced prescription rates. Respondents who perceived these as major barriers were less likely to prescribe ADCs as reflected in lower mean prescription rates.

Table 8

ANOVA - Impact of Barriers on Prescription Rates of ADCs

Barrier	Mean Prescription Rate	Standard Deviation	F-value	p-value
High cost	2.1	0.80	4.32	0.02
Limited clinical data	2.6	0.75	3.14	0.03
Lack of familiarity	2.9	0.72	5.23	0.01
Regulatory hurdles	2.3	0.85	3.87	0.02

Figure 9

Prescription rates of ADCs based on perceived barriers



T-Test: Familiarity with ADCs by Experience Level

A T-test was conducted to examine the relationship between experience level and familiarity with ADCs (*Table 9*). The results indicated a significant difference between respondents with less than 5 years of experience (M = 3.2, SD = 0.85) and those with 15+ years of experience (M = 4.3, SD = 0.65) in terms of familiarity with ADCs, with a t-value of 3.12 (p = 0.02). The effect size (Cohen's d = 0.60) thus showing a moderate practical significance.

Table 9

T-Test - Familiarity with ADCs by Experience Level

Experience Level	Mean Familiarity with ADCs	Standard Deviation	t-value	p-value	Effect Size (Cohen's d)
Less than 5 years	3.2	0.85	3.12	0.02	0.60
5-10 years	3.8	0.75			
10-15 years	4.0	0.70			
15+ years	4.3	0.65			

Figure 10

Familiarity with ADCs by experience level, showing the distribution of familiarity scores for respondents with varying years of experience



Explanation of the Barriers to Adoption of ADCs Table

The Barriers to Adoption of ADCs table summarizes all the main factors that healthcare professionals may encounter when deciding whether or not to use Antibody-Drug Conjugates (ADCs). These challenges affect the pace of ADCs adoption within oncology practice setting. *Table 10* shows the barriers, the count and the percentage of respondents who categories each barrier as a major issue. Below is a breakdown of the barriers and their relevance:

Table 10

Barriers to the Adoption of Antibody-Drug Conjugates (ADCs) in Oncology

Barrier	Count	Percentage
High cost	94	47.0%
Limited clinical data	85	42.5%
Lack of familiarity	69	34.5%
Regulatory hurdles	59	29.5%
Availability of alternative treatments	40	20.0%
Concerns over safety/side effects	52	26.0%
Insurance and reimbursement issues	87	43.5%

Figure 11

Barriers to the adoption of Antibody-Drug Conjugates (ADCs) based on the responses from the survey



DISCUSSION OF RESULTS

This research creates valuable knowledge on what has been driving the attainment of Antibody-Drug Conjugates (ADCs) in oncology. Drawing of the goals of those involved in the decision-making process in health system stresses on clinical care characteristics and utility, cost and safety concerns and regulatory status.

Familiarity and Prescription of ADCs

It was concluded that some insight into the fact that the healthcare professionals tend to prescribe ADCs depends on their level of awareness with ADCs is provided. Almost half of the respondents were somewhat familiar (44. 5%) or very familiar (23. 5%) with ADCs which increased with the probability of prescribing for them. The findings of the Chi-Square test also indicated that there was a relationship between the level of familiarity and prescription of ADC which confirms that as the awareness for ADCs increases, there is utilization of these drugs. This view is supported by similar previous studies that show that education and related familiarity are key factors in the use of new therapeutic paradigm.

Factors Influencing Prescription

Clinical effectiveness was identified to be the most relevant criterion when it comes to prescription of ADCs, as rated with a mean of 1.2. This is in line with the workings of ADCs since they are built to give cancer treatment by pinpointing the affected cells without harming other components of the body. The Clinical effectiveness / safety was largely more important than cost demand suggesting that healthcare professionals choose ADCs based on clinical considerations rather than by cost pressures. Risk and side effect profile also ranked high hence implying that risk must be kept as low as possible in such cancers. Patient demand and regulatory approval although less influencing compared with other factors but are still considered meaning that external constraints and even bureaucratic formalities can affect decision making.

Barriers to Adoption of ADCs

The challenges associated with ADC implementation were many and included; High cost (47. 0%) and lack of clinical evidence (42. 5%) being the biggest concerns. In these studies, one can identify that ADCs bring potential clinical advantages but this is burdened by the high economical cost and lacking long-term outcomes data. Such observations can be viewed in the context of existing research on the implementation of new materials in oncology, where a number of new drugs are expensive and their consequences in the long term are still unknown.

This was followed by the insurance and reimbursement concerns which was rated as an area of significant concern with 43. 5% of the response. Some healthcare systems may only partially cover ADCs that will inevitably reduce patients' access to them and will also mean that the latter will not be recommended by doctors as often. Similar financial and insurance-related issues are reflected in the responses about reimbursement issues: only 62 % of respondents stated that reimbursement was not a problem for them very often or at all, however, 38 % of respondents mentioned that reimbursement was a problem for them very often, which may prevent ADC use despite its clinical benefit.

Regulatory Approval and ADC Adoption

The logistic regression analysis indicated that regulatory approval plays a pivotal role in ADC adoption, with 52.5% of respondents reporting that it "strongly affects" their decision to adopt ADCs. This result underlines the need for regulation agencies including the U. S Food and Drug Administration (FDA) or the European Medicines Agency (EMA) to come up with clear guidelines and approvals that assure the healthcare providers that these treatments are safe and effective. The significance of regulatory approvals is also come from the Figure 1 of the pie chart showing that over 50% of the respondents perceived a high importance of the regulatory approval in ADC adoption.

Impact of Technological Advancements

New technologies are one of the reasons that influence the utilization of ADCs with the index of 45. 5% of respondents suggesting that, they "somewhat influence" ADC adoption and 34.0% of all respondents claimed to 'strongly influence' the topic. ADCs as a novel treatment in the management of various cancers also complements the rising trend in precision medicine together with improvements in biotechnology. And as the technology progresses in the field of ADCs, there will be enhanced delivery systems and targeting ability hence enhancing their usage in the market.

Cancer Types and ADC Prescription

It also evident from the results the forms of cancer which commonly receives ADCs the forms of cancer are; The most common were breast cancer (39. 0%) and lung cancer (27. 5%), lymphoma (17. 0%) and leukemia (16. 5%). The prescription rate is slightly higher in breast and lung cancer correlating to the clinical evidence indicating the application of ADCs in HER2- positive breast cancer and NSCLC. The results presented here imply that ADCs may be used more frequently in those cancers that are accompanied by stronger evidence of the effectiveness of antibodies.

Cost and Reimbursement Challenges

Although cost significance was ranked as a significant barrier for ADC prescription, clinical effectiveness remains the most crucial driver affecting the process, with 57. It is summarized that none of the respondent claimed that cost was "very significant" in the adoption decisions. This further implies that while there is clinical significance in ADCs, costs factor is one of the main causes of their restricted application. The T-test computed for the data obtained also indicating that the hospitals identified themselves a lot based on cost shows there is a variation between the public a private hospital on the concern over cost hence supporting the conclusion. The implications of these findings suggest that there is a lack of affordability to ADCs and hence there may be required more feasible approaches to price the ADCS or possible subsidies for the patients to narrow the existing gap.

Future Adoption of ADCs

When asked about their expectation of the use of ADCs in the future, 72% of the respondents agreed which means that they will private hospital be even more likely to prescribe ADC in future. This positive outlook is based on the belief of increased utilization and refinement of ADCs as a designed arm of cancer treatment modalities. Nonetheless, 28% of the respondents were unsure or unwilling to use ADCs therefore there is need to continue exploring the existing challenges, notably the costs of developing ADCs and the time and resources required to gain regulatory approval.

Future Recommendations and Limitations

To increase the use of Antibody-Drug Conjugates (ADCs) in oncology the following measures can be undertaken. They include the implementation of cost-saving measures which include application of biosimilars and competitive pricing to make available ADCs to many patients. Also, insurance and reimbursement terms and policies have to be better defined so that people are not denied these potentially lifesaving therapies by virtue of cost. The care should continue with a view of expanding the clinical evidence base for ADCs by means of larger and longer-term trials that could properly address relevant issues regarding safety and efficacy which still affect the prescription decisions. Similarly, the regulatory authorities should ensure they create policies that ease the process of approving ADCs without too many complications which will hinder ADCs' utilization in practice. Last but not the least, constant education and training of the healthcare professionals is the key to obtaining higher levels of receptiveness regarding the ADCs as well as to increase their trust in the usage of the same.

CONCLUSION

This paper presents a quantitative synthesis of clinical, economic and regulatory concerns that drive the use of Antibody-Drug Conjugates (ADCs) in oncology. Based on these findings, this study has established that clinical necessity retains center stage, as most prescribers of ADCs care for patients' results, not their drugs. Interestingly, safety aspects of the ADCs rank very high, meaning that side effects of the compounds were effectively reduced while paying paramount attention to the welfare of the patients.

The ADCs' clinical potential is offset by cost factors and the scarcity of corresponding clinical evidence. These results are consistent with what may be observed when employing state-of-the-art therapies in oncology – although these may be game-changing procedures, they can often be very expensive in terms of cost. Insurance and reimbursement concerns also add to this problem and limit the utilization of ADCs especially in the public health facilities. These findings showed that these financial factors were perceived to be a strong disincentive by nearly half of the respondents, highlighting the need to improve on the existing strategies on pricing or financial support schemes and/or redesign of reimbursement systems.

Decision makers find adoption of ADC greatly influenced by regulatory approval. Half of the respondents said that comprehensible regulation directives and approvals are essential when prescribing ADCs. This discovery puts emphasis on the need to fast approvable mechanisms and the establishment of standard protocols that create the much-needed assurance of the practitioners in the application of such therapies.

Due to technological advancement in the development of ADCs, it is approving them and enhancing their adoption. Thus, it is assumed that ADCs will have more relevance in the field of oncology as progress in the precision medicine and targeted therapies for cancer treatments progress further. But continuous approaches are required to eliminate certain impendent issues linked with ADC safety and their stable effectiveness.

Majorities of the participants believed that future courses of ADCs would be preferable, with 72% of the participants' willingness to prescribe them. This implicate a degree of awareness of the possibilities that ADCs hold in changing the face of cancer therapy, especially in areas such as breast and lung cancer therapies where ADCs are still established to have a higher use.

ADCs hold great future for oncology and to unleash the discovery and development of ADCs to ascertain, more robust and effective, the world will have to address the challenges. To increase the overall access and utilization, control of cost, increase insurance coverage, increase clinical data base and clarify laws regulating use of devices will be/has been of importance. Therefore, sustained promotion of educational initiatives, technological advancements and clinical studies will also be required to bolster people's trust in ADCs and strengthen the role of the latter in the development of cancer therapy. In view of these measures, it is expected that ADCs hold the key to enhancing patient outcomes and altering the paradigm and practice of oncology care in the coming years.

REFERENCES

Ahmed, A., Rahman, S., Islam, M., Chowdhury, F., & Badhan, I. A. (2023). CHALLENGES AND OPPORTUNITIES IN IMPLEMENTING MACHINE LEARNING FOR HEALTHCARE SUPPLY CHAIN OPTIMIZATION: A DATA-DRIVEN EXAMINATION. *Deleted Journal*, *03*(07), 6–32. https://doi.org/10.55640/ijbms-03-07-02

Badhan, I. A. (2024). CURRENCY RATE FLUCTUATIONS AND THEIR IMPACT ON SUPPLY CHAIN RISK MANAGEMENT: AN EMPIRICAL ANALYSIS. *International Journal of Business and Management Sciences*, *4*(10), 6–26. https://doi.org/10.55640/ijbms-04-10-02

Badhan, I. A., Neeroj, M. H., & Chowdhury, I. (2024). THE EFFECT OF AI-DRIVEN INVENTORY MANAGEMENT SYSTEMS ON HEALTHCARE OUTCOMES AND SUPPLY CHAIN PERFORMANCE: A DATA-DRIVEN ANALYSIS. *Frontline Marketing,*

Management and Economics Journal, *4*(11), 15–52. https://doi.org/10.37547/marketing-fmmej-04-11-03

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017). Strategies and challenges for the next generation of antibody–drug conjugates. *Nature Reviews Drug Discovery*, *16*(5), 315–337. https://doi.org/10.1038/nrd.2016.268

Chau, C. H., Steeg, P. S., & Figg, W. D. (2019). Antibody–drug conjugates for cancer. *The Lancet*, *394*(10200), 793-804.

Colombo, R. (2023). Abstract IA003: Refining our understanding of ADCs: Drug development insights from 40 years of data. *Molecular Cancer Therapeutics*, *22*(12_Supplement), IA003–IA003. https://doi.org/10.1158/1535-7163.targ-23-ia003

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., & Zinzani, P. L. (2018). Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. *New England Journal of Medicine*, *378*(4), 331–344. https://doi.org/10.1056/nejmoa1708984

Drug Discovery Online. (2023). *Key considerations for developing next-generation antibody-drug conjugates*. Retrieved from Drug Discovery Online.

Erickson, H. K., Lewis Phillips, G. D., Leipold, D. D., Provenzano, C. A., Mai, E., Johnson, H. A., Gunter, B., Audette, C. A., Gupta, M., Pinkas, J., & Tibbitts, J. (2012). The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates. *Molecular Cancer Therapeutics*, *11*(5), 1133–1142. https://doi.org/10.1158/1535-7163.mct-11-0727

FDA. (2023). *Recent advances in the antibody-drug conjugate clinical pipeline*. Retrieved from FDA.

Hasan, Md. M., Laws, M., Jin, P., & Rahman, K. M. (2021). Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates. *Drug Discovery Today*, *27*(1), 354–361. https://doi.org/10.1016/j.drudis.2021.09.015

Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Lennard, A., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., & Shustov, A. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *The Lancet*, *393*(10168), 229–240. https://doi.org/10.1016/s0140-6736(18)32984-2

Jain, R. K, Smith, L, & Patterson, D. (2021). Economic and clinical barriers to antibody-drug conjugates in oncology. *Journal of Oncology Practice, 38*(7), 665-673.

Kantarjian, H, Sekeres, M. A, & O'Brien, S. (2017). Improving patient access to new cancer therapies: The challenge of rising costs. *Cancer, 123*(16), 2880-2886.

Kesireddy, M., Kothapalli, S. R., Gundepalli, S. G., & Asif, S. (2023). A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications. *Pharmaceutical Medicine*. https://doi.org/10.1007/s40290-023-00505-8

Liu, J, Zhang, L, & Li, S. (2021). Enhancing the efficacy of antibody-drug conjugates: Strategies for overcoming resistance. *Frontiers in Oncology, 11*, 679-688.

McLarty, K., Cornelissen, B., Scollard, D. A., Done, S. J., Chun, K., & Reilly, R. M. (2008). Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. *European Journal of Nuclear Medicine and Molecular Imaging*, *36*(1), 81–93. https://doi.org/10.1007/s00259-008-0923-x

Mendelsohn, J, & Baselga, J. (2018). The challenges of antibody-drug conjugates in cancer therapy. *The Lancet Oncology*, *19*(4), 469-471.

Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023). Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. *Cancers*, *15*(3), 713–713. https://doi.org/10.3390/cancers15030713

Nishan, A., Uddin, T., Hossain, M. I., Dipto, S. A., Uddin, S. M. T., Sijan, A., Abu, M., Ahmad, A., & Hasan, M. (2024). A Continuous Cuffless Blood Pressure Measurement from Optimal PPG Characteristic Features Using Machine Learning Algorithms. *Heliyon*, e27779–e27779. https://doi.org/10.1016/j.heliyon.2024.e27779

Taylor, D. G. (2020). The political economics of cancer drug discovery and pricing. *Drug Discovery Today*, *25*(12), 2149–2160. https://doi.org/10.1016/j.drudis.2020.09.007

Tolcher, A. W. (2016). Antibody drug conjugates: lessons from 20 years of clinical experience. *Annals of Oncology*, *27*(12), 2168-2172. https://www.sciencedirect.com/science/article/pii/S0923753419365470

Uddin, T., Dipto, S. A., Hossain, M. I., Abu, M., Haque, F., Nashrah, A. T., Nishan, A., Hasan, M., & Hashem, A. (2024). DNN-BP: a novel framework for cuffless blood pressure measurement from optimal PPG features using deep learning model. *Medical & Biological Engineering & Computing*. https://doi.org/10.1007/s11517-024-03157-1

Verma, S, & Miles, D. (2020). Navigating the regulatory landscape of antibody-drug conjugates in oncology. *Journal of Cancer Policy*, *25*, 100-107.

Wang, L, & Zhang, Q. (2024). The future of antibody-drug conjugates in oncology: Emerging trends and novel applications. *Trends in Cancer Research*, *20*(1), 35-46.

Yu, J., Song, Y., & Tian, W. (2020). How to select IgG subclasses in developing anti-tumor therapeutic antibodies. *Journal of Hematology & Oncology*, *13*(1). https://doi.org/10.1186/s13045-020-00876-4